Navigating the Hormonal Journey: A Clinician's Guide to Perimenopause, Menopause, and Global Variation in Care

Menopause isn't a single event — it's a years-long hormonal unwinding, unstable long before it settles. As the follicle pool shrinks, inhibin B drops first, freeing FSH to climb; progesterone gives way years before estrogen does, and AMH declines more steadily. STRAW+10 remains the framework clinicians lean on to stage where a woman sits, using cycle-length changes and time since her last period rather than a blood draw. Early postmenopause under this framework actually runs five to eight years, not the one or two often assumed. Once estrogen settles low, effects show up everywhere at once, not one system at a time. Severe hot flashes track with higher cardiovascular and bone risk down the line — an association worth stressing, not a proven cause — mood and brain fog seem tied more to how sharply hormones swing than how low they go; lipids, bone density, and midsection weight gain move together; and vaginal and urinary symptoms, unlike hot flashes, don't fade with time if left alone. Individualised, timing-aware hormone therapy is still the most effective tool available for symptoms — it treats hot flashes and protects bone, not the heart — transdermal estradiol especially for cardiometabolic risk, with SSRIs, SNRIs, and newer neurokinin antagonists (fezolinetant and now, elinzanetant) as real options for women who can't use hormones. This review also looks at how unevenly this care is delivered worldwide: primary care hands out prescriptions readily in the UK and Australia, while women in the Gulf often see several specialists before hormone therapy comes up. How much of that gap comes from the health system itself, rather than biology, is a question this review keeps returning to. Keywords: Perimenopause, Menopause, Menopausal hormone therapy (MHT), Vasomotor symptoms, STRAW+10 staging, Genitourinary syndrome of menopause, Global health disparities, Estrogen.